Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Chlamydocin is a histone deacetylase (HDAC) inhibitor that was originally isolated from D. chlamydosporia and has anticancer properties.1 It is selective for HDAC1 over HDAC6 (IC50 = 0.15 and 1,100 nM, respectively).2 Chlamydocin increases acetylation of histone H3 and histone H4 in A2780 cells when used at concentrations ranging from 1 to 1,000 nM.1 It inhibits growth of A2780, Malme-3M, MCF-7, HT-29, and HeLa cancer cells (IC50s = 0.36, 45, 5.3, 4.3, and 14 nM, respectively). Chlamydocin increases lifespan by 10% in a P185 mouse allograft model when administered at doses ranging from 20 to 160 mg/kg.3
WARNING This product is not for human or veterinary use.
1. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-
2. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 98(1), 87-92 (2001).
3. Cytostatic activity of chlamydocin, a rapidly inactivated cyclic tetrapeptide. Eur. J. Cancer 10(12), 801-808 (1974).